Microfluidic-Based Multi-Organ Platforms for Drug Discovery
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Development of predictive multi-organ models before implementing costly clinical trials is central for screening the toxicity, efficacy, and side effects of new therapeutic agents. Despite significant efforts that have been recently made to develop biomimetic in vitro tissue models, the clinical application of such platforms is still far from reality. Recent advances in physiologically-based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling, micro- and nanotechnology, and in silico modeling have enabled single- and multi-organ platforms for investigation of new chemical agents and tissue-tissue interactions. This review provides an overview of the principles of designing microfluidic-based organ-on-chip models for drug testing and highlights current state-of-the-art in developing predictive multi-organ models for studying the cross-talk of interconnected organs. We further discuss the challenges associated with establishing a predictive body-on-chip (BOC) model such as the scaling, cell types, the common medium, and principles of the study design for characterizing the interaction of drugs with multiple targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 8×
“The organ-on-chip platforms are also well-suited for investigating tissue-tis ue interactions through cu turing multi le cell types posi ioned parately in several microchan els while interconnected by membrane or porous substrates [78,79,98].”
BackgroundMethodInfluentialElectrochemical Glucose Biosensors
Wang, J. (2008) · Chemical Reviews · doi:10.1021/cr068123a · Cited by 3,498 · cited 1×
“While electrochemical biosensors generally suffer from deterioration of stability of biological elements like enzymes, and insufficient selectivity and specificity [268,297,298], the recent advances in surface chemistry and surface functionalization have improved the performance of electrodes and made this type of bio…”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Geometric cues for directing the differentiation of mesenchymal stem cells
Kilian, K. A., Bugarija, B., Lahn, B. T., & Mrksich, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903269107 · Cited by 1,841
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“In the drug-based approaches, the chemical perspective of drug molecules is considered such as the structural features [227–230], the biological action of drugs [231–234], and the molecular docking [235].”
BackgroundLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
25th Anniversary Article: Rational Design and Applications of Hydrogels in Regenerative Medicine
Annabi, N., Tamayol, A., Uquillas, J. A., Akbari, M., Bertassoni, L. E., Cha, C., Camci‐Unal, G., Dokmeci, M. R., Peppas, N. A., & Khademhosseini, A. (2014) · Advanced Materials · doi:10.1002/adma.201303233 · Cited by 1,409
Self-citationMolecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299 · cited 1×
“Malignant tumor cells and other cells existing in the tumor microenvironment such as fibroblasts, endothelial cells, leukocytes, and hematopoietic cells can form organoid constructs [66–69].”
BackgroundDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 1×
“On the other hand, in the disease-based methods, the clinical perspective or pathology of the disease is considered as in methods using shared molecular pathology [236–239] and side effect similarity [221,240].”
MethodGrowing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
Sato, T., & Clevers, H. (2013) · Science · doi:10.1126/science.1234852 · Cited by 1,170
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993 · cited 4×
“mimic activities such as breathing (Figure 3a) [78,79], cardiovascular contraction and pumping, as well as peristalsis cycling in the gut (Figure 3b) [80].”
BackgroundInfluentialKelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797 · cited 1×
“In these multicellular aggregates, the need to supporting gels or matrices is eliminated [10], the adverse influence of adhesion to artificial surfaces is removed [11], and therapeutic agents are more reliably experimented [12].”
BackgroundReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748 · cited 2×
“The primary focus in pre-clinical models is on using absorption, distribution, metabolism and excretion (ADME) methods and other prediction and validation tools as an upgraded technology for the rapid recognition of adverse side effects or failure of pharmaceutical candidates [149].”
BackgroundMethodAnimal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Microfluidic 3D cell culture: from tools to tissue models
van Duinen, V., Trietsch, S. J., Joore, J., Vulto, P., & Hankemeier, T. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.05.002 · Cited by 500 · cited 1×
“Conventional 2D tissue models such as culturing in Petri dishes are still common in laboratory studies, but these cell assemblies are severely limited in mimicking cell-cell and cell-matrix interaction, and some other vital morphological and biochemical features [45].”
BackgroundEngineered Microenvironments for Controlled Stem Cell Differentiation
Burdick, J. A., & Vunjak-Novakovic, G. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2008.0131 · Cited by 485 · cited 1×
“Biophysical properties such as geometric cues [119] provided within microfluidic chips have proven advantages in lineage differentiation [120] and gene expression profiling [121,122].”
BackgroundWagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 2×
“(a) The 3D schematic of the liver-skin co-culture microfluidic device; and (b) The metabolic activity of the co-culture of liver and skin [158].”
BackgroundOrgan-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
Xu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., Wang, W., Gao, Z., & Wang, Q. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.045 · Cited by 295
Cell viability assessment using the Alamar blue assay: A comparison of 2D and 3D cell culture models
Bonnier, F., Keating, M. E., Wróbel, T. P., Majzner, K., Baranska, M., Garcia-Munoz, A., Blanco, A., & Byrne, H. J. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.09.014 · Cited by 276 · cited 1×
“The literature has shown metabolic and functional differences between 2D and 3D tissue models [180,181].”
BackgroundHyder, F., Rothman, D. L., & Bennett, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214912110 · Cited by 271 · cited 1×
“Allometric scaling may not be authentic for all type of organs [197,198].”
BackgroundYamada, M., Utoh, R., Ohashi, K., Tatsumi, K., Yamato, M., Okano, T., & Seki, M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.068 · Cited by 247
Clissold, S. P. (1986) · Drugs · doi:10.2165/00003495-198600324-00005 · Cited by 244
In vitro model of tumor cell extravasation
Jeon, J. S., Zervantonakis, I. K., Chung, S., Kamm, R. D., & Charest, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056910 · Cited by 233 · cited 2×
“Furthermore, static in vitro cell cultures cannot maintain metabolic activities for the relevant lifespan [132].”
BackgroundDouville, N. J., Zamankhan, P., Tung, Y.-C., Li, R., Vaughan, B. L., Tai, C.-F., White, J., Christensen, P. J., Grotberg, J. B., & Takayama, S. (2011) · Lab Chip · doi:10.1039/c0lc00251h · Cited by 216 · cited 1×
“Researchers combined the mechanical [172,173], biomaterial [174,175], and topographical [176] characteristics on in vitro models to recreate in vivo functionality as a novel approach towards drug testing.”
BackgroundGardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
Nguyen, T. A., Yin, T.-I., Reyes, D., & Urban, G. A. (2013) · Analytical Chemistry · doi:10.1021/ac402761s · Cited by 189
In vitro analysis of a hepatic device with intrinsic microvascular-based channels
Carraro, A., Hsu, W.-M., Kulig, K. M., Cheung, W. S., Miller, M. L., Weinberg, E. J., Swart, E. F., Kaazempur-Mofrad, M., Borenstein, J. T., Vacanti, J. P., et al. (2008) · Biomedical Microdevices · doi:10.1007/s10544-008-9194-3 · Cited by 168
On being the right size: scaling effects in designing a human-on-a-chip
Moraes, C., Labuz, J. M., Leung, B. M., Inoue, M., Chun, T.-H., & Takayama, S. (2013) · Integrative Biology · doi:10.1039/c3ib40040a · Cited by 134
Belair, D. G., Whisler, J. A., Valdez, J., Velazquez, J., Molenda, J. A., Vickerman, V., Lewis, R., Daigh, C., Hansen, T. D., Mann, D. A., et al. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9549-5 · Cited by 120 · cited 1×
“Recently, hiPSCs derivatives within microfluidics became popular among research groups to spatiotemporally differentiate these cells inside the chip, and optimize the delivery of exogenous factors and remove cell-secreted factors, for applications like vascular modeling and drug screening [101,117,212,213].”
BackgroundMicroengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116 · cited 1×
“The liver has been extensively considered as the prime organ for drug toxicity analyses as most of the drug metabolisms occur in the liver [71,156,157].”
BackgroundA microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids
Ruppen, J., Cortes-Dericks, L., Marconi, E., Karoubi, G., Schmid, R. A., Peng, R., Marti, T. M., & Guenat, O. T. (2014) · Lab Chip · doi:10.1039/c3lc51093j · Cited by 105 · cited 1×
“In more advanced systems, organoids are formed and characterized either off-chip within conventional well plates and then manipulated by the pipetting [11,54] or cultured inside a microfluidic system, providing a flow of nutrients to cells [55].”
BackgroundAccurate prediction of human drug toxicity: a major challenge in drug development
Li, A. P. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.008 · Cited by 82
Zhang, J. D., Berntenis, N., Roth, A., & Ebeling, M. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.39 · Cited by 79
Gessner, R. C., Hanson, A. D., Feingold, S., Cashion, A. T., Corcimaru, A., Wu, B. T., Mullins, C. R., Aylward, S. R., Reid, L. M., & Dayton, P. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.033 · Cited by 44
In vitro micro-physiological models for translational immunology
Ramadan, Q., & Gijs, M. A. M. (2015) · Lab on a Chip · doi:10.1039/c4lc01271b · Cited by 41 · cited 1×
“The existence of media perfusion is one major advantage of microfluidic systems [74], which allows supplying essential nutrients and oxygen to tissues in physiologically-relevant residence spans.”
Background
Cited by
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Self-citationEvolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip
Azizipour, N., Avazpour, R., Rosenzweig, D. H., Sawan, M., & Ajji, A. (2020) · Micromachines · doi:10.3390/mi11060599 · Cited by 277
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Self-citationDrug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review
Cong, Y., Han, X., Wang, Y., Chen, Z., Lu, Y., Liu, T., Wu, Z., Jin, Y., Luo, Y., & Zhang, X. (2020) · Micromachines · doi:10.3390/mi11040381 · Cited by 140
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
Metadata
- Authors
- Rezaei Kolahchi, A., Khadem Mohtaram, N., Pezeshgi Modarres, H., Mohammadi, M., Geraili, A., Jafari, P., Akbari, M., & Sanati-Nezhad, A.
- Venue
- Micromachines
- Publisher
- MDPI AG
- Published
- 2016-09-08
- Volume
- 7
- Issue
- 9
- Pages
- 162
- ISSN
- 2072-666X (ISSN-L)
- OpenAlex
- W2509960233
- Cited by
- 53
- References
- 46
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.